Rituximab alone provides extended remission in follicular lymphoma

rituximab.jpg

Results of the Swiss Group for Clinical Cancer Research (SAKK) Trial 35/98 have been published, and the results indicate potential extra benefits to long-term single-agent rituximab in certain patients with follicular lymphoma

Read more of this story at CancerTreatment.net.

LymphomaInfo Social